Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats
- PMID: 1549643
- DOI: 10.1007/BF02801966
Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats
Abstract
Persistent tardive dyskinesia is a serious side effect of long-term treatment with neuroleptics. Although striatal pathologic changes are believed to underlie this potentially irreversible iatrogenic syndrome, the nature of the neuroleptic-induced neuropathology is unclear. In the present study, we treated rats with either vehicle or fluphenazine decanoate (5 mg/kg, IM) every 2 weeks for 4, 8 or 12 months. Four to nine weeks after the last injection, the animals were sacrificed and the density of cells in the central part of the striatum was measured with a computerized image-analysis system. The control and experimental animals did not differ in body weight with 4 and 8 months of treatment, but the rats treated with fluphenazine for 12 months had significantly lower body weights than comparable controls. Four months of neuroleptic use produced no significant neuropathologic changes. The animals treated with fluphenazine for 8 months had a significantly lower density of the large neurons. In the 12-month-treated group, there was no significant difference between the control and experimental animals, probably because of a 'floor effect': the density of the large neurons was significantly lower in the 12-month-treated compared to the 8-month-treated control rats.
Similar articles
-
Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods.Psychopharmacology (Berl). 2000 Feb;148(2):171-9. doi: 10.1007/s002130050039. Psychopharmacology (Berl). 2000. PMID: 10663432
-
Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.Neuroscience. 2003;119(2):547-55. doi: 10.1016/s0306-4522(03)00170-2. Neuroscience. 2003. PMID: 12770567
-
Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.Neuroscience. 1998 Dec;87(3):639-48. doi: 10.1016/s0306-4522(98)00160-2. Neuroscience. 1998. PMID: 9758230
-
Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.Nature. 1984 May 24-30;309(5966):347-9. doi: 10.1038/309347a0. Nature. 1984. PMID: 6727989
-
Fluphenazine-induced acute and tardive dyskinesias in monkeys.Psychopharmacology (Berl). 1984;84(3):310-4. doi: 10.1007/BF00555204. Psychopharmacology (Berl). 1984. PMID: 6440175
Cited by
-
GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.Psychopharmacology (Berl). 1994 Dec;116(4):517-22. doi: 10.1007/BF02247487. Psychopharmacology (Berl). 1994. PMID: 7701057
-
Relevance of animal models to human tardive dyskinesia.Behav Brain Funct. 2012 Mar 9;8:12. doi: 10.1186/1744-9081-8-12. Behav Brain Funct. 2012. PMID: 22404856 Free PMC article. Review.
-
Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.Psychopharmacology (Berl). 1996 Jun;125(3):238-47. doi: 10.1007/BF02247334. Psychopharmacology (Berl). 1996. PMID: 8815959
-
The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia?Psychopharmacology (Berl). 1995 Jun;119(4):474-6. doi: 10.1007/BF02245864. Psychopharmacology (Berl). 1995. PMID: 7480528
-
Pathophysiology, prognosis and treatment of tardive dyskinesia.Ther Adv Psychopharmacol. 2022 Oct 21;12:20451253221117313. doi: 10.1177/20451253221117313. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36312846 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources